Your browser doesn't support javascript.
loading
Use of artificial intelligence chatbots in clinical management of immune-related adverse events.
Burnette, Hannah; Pabani, Aliyah; von Itzstein, Mitchell S; Switzer, Benjamin; Fan, Run; Ye, Fei; Puzanov, Igor; Naidoo, Jarushka; Ascierto, Paolo A; Gerber, David E; Ernstoff, Marc S; Johnson, Douglas B.
Affiliation
  • Burnette H; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Pabani A; Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
  • von Itzstein MS; Harold C Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Switzer B; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Fan R; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Ye F; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Naidoo J; RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland.
  • Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
  • Gerber DE; Harold C Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Ernstoff MS; ImmunoOncology Branch (IOB), Developmental Therapeutics Program, Cancer Therapy and Diagnosis Division, National Cancer Institute (NCI), National Institutes of Health, Bethesda, Maryland, USA.
  • Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA douglas.b.johnson@vumc.org.
J Immunother Cancer ; 12(5)2024 May 30.
Article in En | MEDLINE | ID: mdl-38816231
ABSTRACT

BACKGROUND:

Artificial intelligence (AI) chatbots have become a major source of general and medical information, though their accuracy and completeness are still being assessed. Their utility to answer questions surrounding immune-related adverse events (irAEs), common and potentially dangerous toxicities from cancer immunotherapy, are not well defined.

METHODS:

We developed 50 distinct questions with answers in available guidelines surrounding 10 irAE categories and queried two AI chatbots (ChatGPT and Bard), along with an additional 20 patient-specific scenarios. Experts in irAE management scored answers for accuracy and completion using a Likert scale ranging from 1 (least accurate/complete) to 4 (most accurate/complete). Answers across categories and across engines were compared.

RESULTS:

Overall, both engines scored highly for accuracy (mean scores for ChatGPT and Bard were 3.87 vs 3.5, p<0.01) and completeness (3.83 vs 3.46, p<0.01). Scores of 1-2 (completely or mostly inaccurate or incomplete) were particularly rare for ChatGPT (6/800 answer-ratings, 0.75%). Of the 50 questions, all eight physician raters gave ChatGPT a rating of 4 (fully accurate or complete) for 22 questions (for accuracy) and 16 questions (for completeness). In the 20 patient scenarios, the average accuracy score was 3.725 (median 4) and the average completeness was 3.61 (median 4).

CONCLUSIONS:

AI chatbots provided largely accurate and complete information regarding irAEs, and wildly inaccurate information ("hallucinations") was uncommon. However, until accuracy and completeness increases further, appropriate guidelines remain the gold standard to follow.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Artificial Intelligence Limits: Humans Language: En Journal: J Immunother Cancer Year: 2024 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Artificial Intelligence Limits: Humans Language: En Journal: J Immunother Cancer Year: 2024 Document type: Article Affiliation country: Estados Unidos